By Maxx Chatsko The synthetic biology leader’s healthy cash balance provides plenty of breathing room, but it won’t last forever. Ginkgo Bioworks (DNA) has certainly caught the attention of investors. The shine may have worn off a bit considering the trendy stock’s 65% nosedive since the beginning of 2022, but the power of synthetic biology means there’s an infinite well of hope to tap into. The details of the company’s public debut in 2021 help to explain much of the stock’s decline. Ginkgo Bioworks launched through a SPAC that handed it a market valuation of over $15 billion — almost four t…